Adoptive Therapy with T Cells/NK Cells

Biology of Blood and Marrow Transplantation

Volumn 13, Issue SUPPL. 1, 2007, Pages 33-42

  Cooley, Sarah ^a   June, Carl H ^b   Schoenberger, Stephen P ^c   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Immunotherapy; NK cells; T cells; Vaccines

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2; PNEUMOCOCCUS VACCINE; VACCINE;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CELL TYPE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MEGADOSE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VIVO STUDY; INNATE IMMUNITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL; REGULATORY T LYMPHOCYTE; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; VACCINATION;

EID: 33845994384     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.10.008     Document Type: Article

References (40)

1. Lanier L.L. NK cell recognition. Annu Rev Immunol 23 (2005) 225-274
2. Rosenberg S.A., Lotze M.T., Muul L.M., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316 (1987) 889-897
3. Burns L.J., Weisdorf D.J., DeFor T.E., et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 32 (2003) 177-186
4. Dummer W., Niethammer A.G., Baccala R., et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 110 (2002) 185-192
5. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
6. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
7. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057
8. Prlic M., Blazar B.R., Farrar M.A., and Jameson S.C. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 197 (2003) 967-976
9. + T cells. J Exp Med 193 (2001) 219-231
10. Miller J.S., Oelkers S., Verfaillie C., and McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood 80 (1992) 2221-2229
11. Miller J.S., and McCullar V. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 98 (2001) 705-713
12. Uherek C., Tonn T., Uherek B., et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100 (2002) 1265-1273
13. + regulatory T cells. Proc Natl Acad Sci U S A 103 (2006) 5460-5465
14. Koh C.Y., Blazar B.R., George T., et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97 (2001) 3132-3137
15. Zhou J., Shen X., Huang J., Hodes R.J., Rosenberg S.A., and Robbins P.F. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 175 (2005) 7046-7052
16. Bevan M.J. Helping the CD8(+) T cell response. Nat Rev Immunol 4 (2004) 595-602
17. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., and Restifo N.P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 26 (2005) 111-117
18. Rapoport A.P., Stadtmauer E.A., Agui N., et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T cell transfer. Nat Med 11 (2005) 1230-1237
19. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., and Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257 (1992) 238-241
20. Mori S., Kocak U., Shaw J.L., and Mullen C.A. Augmentation of post-transplant immunity: antigen encounter at the time of hematopoietic stem cell transplantation enhances antigen-specific donor T cell responses in the post-transplant repertoire. Bone Marrow Transplant 35 (2005) 793-801
21. Wang L.X., Li R., Yang G., et al. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 65 (2005) 10569-10577
22. Neelapu S.S., Munshi N.C., Jagannath S., et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 36 (2005) 315-323
23. +-selected hematopoietic cell transplantation. Blood 102 (2003) 2004-2013
24. + T cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. Clin Cancer Res 5 (1999) 461-469
25. Chang A.E., Aruga A., Cameron M.J., et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15 (1997) 796-807
26. Hsu F.J., Benike C., Fagnoni F., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2 (1996) 52-58
27. + T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A 91 (1994) 5700-5704
28. Kircher M.F., Allport J.R., Graves E.E., et al. In vivo high-resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 63 (2003) 6838-6846
29. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 8 (2002) 47-53
30. Greenberg P.D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49 (1991) 281-355
31. + T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J Clin Oncol 16 (1998) 2752-2760
32. Kwak L.W., Campbell M.J., Czerwinski D.K., Hart S., Miller R.A., and Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327 (1992) 1209-1215
33. Masopust D., Kaech S.M., Wherry E.J., and Ahmed R. The role of programming in memory T cell development. Curr Opin Immunol 16 (2004) 217-225
34. Kaech S.M., Wherry E.J., and Ahmed R. Effector and memory T cell differentiation: implications for vaccine development. Nat Rev Immunol 2 (2002) 251-262
35. + T lymphocytes. Nature 421 (2003) 852-856
36. + T cells after acute infection. Nat Immunol 5 (2004) 927-933
37. + T cell memory via TRAIL-mediated activation-induced cell death. Nature 434 (2005) 88-93
38. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271 (1996) 12687-12690
39. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
40. Diehl G.E., Yue H.H., Hsieh K., et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21 (2004) 877-889